%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.Analyst Target
Analyst consensus price target: $15.00.What is LENSAR Inc?
, a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System.
LNSR · Verdict
Solid reward · moderate risk
LNSR stands out on balance sheet and growth, but watch the profitability signal.
Based on 88% data coverage
LNSR · Verdict
What’s working & what to watch
Strengths 4
- Balance sheet83/100
Current ratio 2.80
- Growth75/100
Rev +15.8% CAGR · earnings +17.0%
- Valuation67/100
Above average
- Volatility65/100
Above average
Watchouts 2
- Profitability24/100
-59% net margin · -422% ROE
- Cash flow25/100
-5% free-cash-flow margin
Model-based scoring. For information only — not financial advice.
What is LENSAR Inc?
, a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 145.01M.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (58)The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.